GET DAILY SIGNALSActinium Pharmaceuticals (ATNM) Stock Advances +55% on Clinical Pipeline Momentum
Key Takeaways
- ATNM shares climbed roughly 55% over the last 30 days, rising from about $1.06 to $1.64.
- The move extended a broader rebound of roughly 70% off mid-August levels near $0.96.
- Momentum centered on ATNM-400, a first-in-class HER3-targeting Actinium-225 radiotherapy, after first-in-human data were presented at EANM and ESMO.
- Enrollment in the RADIANZ imaging trial and accepted ASH and SABCS abstracts reinforced the company's pan-cancer pipeline narrative.
- Analyst coverage turned more constructive, with a maintained Buy rating and a $4.00 price target alongside a Moderate Buy consensus.
Company Overview and Market Position
Actinium Pharmaceuticals, Inc. (ATNM) is a clinical-stage biopharmaceutical company pioneering targeted radiotherapies known as antibody radioconjugates (ARCs). These therapies pair tumor-seeking monoclonal antibodies with the alpha-emitting isotope Actinium-225, which delivers high-energy radiation directly to cancer cells while aiming to spare healthy tissue.
The company's pipeline spans several programs. Actimab-A is a CD33-targeting ARC being developed as a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies, in part under a Cooperative Research and Development Agreement with the National Cancer Institute. ATNM-400 is a first-in-class, HER3-targeting ARC focused on solid tumors, including prostate, lung, breast, colorectal, pancreatic, and ovarian cancers. Iomab-B is a CD45-targeting conditioning agent for patients with relapsed or refractory AML undergoing bone marrow transplant, while Iomab-ACT is a conditioning platform for CAR-T and gene-edited cell therapies, including sickle cell disease. With a broad patent portfolio, proprietary Ac-225 production technology, and no debt, Actinium occupies a differentiated position within the growing radiopharmaceuticals sector. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ATNM advanced approximately 55%, moving from a close near $1.06 in mid-October to $1.64 by mid-November. The gains were not linear: the stock consolidated in a range around $1.30 to $1.50 through late October and early November before pressing higher as clinical news accumulated.
The last quarter tells a similar, larger story. From a close near $0.96 in mid-August, the stock has risen roughly 70%, reflecting a sustained re-rating driven by clinical data flow and improved regulatory clarity rather than a single isolated catalyst.
What Drove the Stock in the Last 30 Days
The 30-day advance coincided with one of the most data-intensive stretches in the company's recent history. In October, Actinium presented initial first-in-human Phase 1 results for ATNM-400 in metastatic castration-resistant prostate cancer as an oral presentation at the European Association of Nuclear Medicine (EANM) annual congress, with the program also featured at the ESMO Congress 2026. The data showed no dose-limiting toxicities in the first patients dosed, HER3-targeted PET imaging with tumor uptake retained through Day 7, and dose escalation advancing to 1.5 µCi/kg.
That momentum carried into November. The company announced acceptance of an ATNM-400 abstract for the San Antonio Breast Cancer Symposium (SABCS) and three ASH 2026 abstracts covering Iomab-ACT in CAR-T therapy and sickle cell disease, along with long-term Actimab-A results in relapsed or refractory AML. Actinium also formed a Scientific Advisory Board, announced enrollment in the RADIANZ imaging trial intended to demonstrate ATNM-400's pan-cancer potential, and hosted a key opinion leader webinar. On the analyst front, H.C. Wainwright maintained a Buy rating with a $4.00 price target, with a broader Moderate Buy consensus around $3.50, reinforcing positive sentiment. From what I see, this steady flow of updates has been key to the re-rating.
What Drove Performance Over the Last Quarter
The quarterly trend reflects a multi-month repricing of risk. In August, Actinium reported that NYSE Regulation had accepted its plan to regain compliance with continued listing standards, granting a plan period through late November 2027 and removing a key overhang. The company also announced Actimab-A intellectual property and manufacturing advances, including expansion of manufacturing capacity ahead of clinical milestones.
Beyond company-specific news, the radiopharmaceuticals space has attracted growing investor attention as alpha-emitter therapies demonstrate differentiated clinical profiles. Actinium's steady cadence of preclinical and clinical updates across ATNM-400, Actimab-A, and Iomab-ACT gave investors multiple reasons to re-evaluate the stock, turning a depressed valuation under $1 into a sustained upward trend. I’m watching this closely as the sector continues to draw interest.
Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to focus on several catalysts. The presentation of additional ATNM-400 breast cancer data at the San Antonio Breast Cancer Symposium in December, and further details from the RADIANZ imaging study, could clarify the program's pan-cancer potential. Actimab-A's planned Phase 2/3 trial in relapsed or refractory AML and proof-of-concept data for Iomab-ACT in CAR-T and sickle cell conditioning represent longer-term milestones. Continued progress toward manufacturing scale-up and maintenance of NYSE American listing compliance will also be monitored. As a clinical-stage company with limited revenue, Actinium's outlook remains tied to clinical execution, regulatory milestones, and its ability to maintain a sufficient cash runway.
Exploring AI Tools in My Research Process
In my analysis of names like ATNM, I often rely on Tickeron’s AI Trading Bots to test automated strategies against recent momentum. The platform draws from a broad set of bots covering thousands of tickers, allowing quick comparison of approaches that align with current conditions. It has become a practical part of staying disciplined when evaluating clinical-stage opportunities. AI Trading Bots
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
ATNM sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for ATNM moved above the 200-day moving average on October 20, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on ATNM as a result. In 75 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for ATNM just turned positive on November 10, 2026. Looking at past instances where ATNM's MACD turned positive, the stock continued to rise in 37 of 51 cases over the following month. The odds of a continued upward trend are 73%.
ATNM moved above its 50-day moving average on October 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ATNM crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Following a +3.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATNM advanced for three days, in 168 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Bearish Trend Analysis
The 10-day RSI Indicator for ATNM moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 18 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ATNM broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ATNM entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ATNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.484) is normal, around the industry mean (3.498). P/E Ratio (4.086) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.105) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers
Industry Biotechnology
Advertisement